Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2022-09-21 Share Issue/Capital Cha…
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
In terms of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, we wish to inform you that the Board of Directors of the Company at their ....
Share Issue/Capital Change Classification · 95% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the outcome of a Board of Directors meeting. It details the allotment of equity shares arising from the conversion of fully convertible warrants, including specifics about the number of shares allotted, dates, and regulatory compliance references (SEBI regulations). The document does not contain financial statements or detailed financial analysis but is an announcement of a corporate action related to capital structure changes (conversion of warrants to equity shares and increase in total equity shares). This fits the category of a Share Issue/Capital Change announcement rather than a full financial report or other types of filings. The document length is 4681 characters, which is consistent with a detailed announcement rather than a full report. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2022-09-21 English
Loss of share certificate
Regulatory Filings
2022-09-19 English
Pursuant to the Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find attached herewith ....
Regulatory Filings
2022-09-19 English
Pursuant to the Regulation 39(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, please find attached herewith ....
Regulatory Filings
2022-09-13 English
Loss of share certificate
Regulatory Filings
2022-09-13 English
Loss of share certificate
Regulatory Filings
2022-09-06 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.